한글목차

세계 바이오뱅크 시장의 미래는 제약 및 생명공학 기업, CRO, 학술 및 연구기관, 병원 시장에 기회가 있어 유망한 것으로 평가되고 있습니다. 세계 바이오뱅크 시장은 2025년부터 2031년까지 10.5%의 연평균 복합 성장률(CAGR)로 2031년 약 68억 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 유전자 검사 및 정밀의료에 대한 수요 증가, 신생아 제대혈 줄기세포 보존의 인기 증가, 가상 바이오뱅크 소프트웨어의 등장입니다.

• Lucintel의 예측에 따르면, 제품 및 서비스별로는 장비가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예측됩니다.
• 용도별로는 재생의료가 예측 기간 동안 가장 큰 부문을 차지할 것으로 예측됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예측됩니다.

바이오뱅크 시장의 전략적 성장 기회

바이오뱅크 시장에는 다양한 용도 측면에서 여러 가지 성장 기회가 존재합니다. 이러한 기회를 활용함으로써 이해관계자들은 연구와 공중보건에 대한 참여를 확대하고 궁극적으로 영향을 미칠 수 있습니다. 이 개요는 바이오뱅크의 프레임워크에서 성장 역학에 초점을 맞추고 주요 성장 패턴과 시장 영역 확장으로 정의되는 광범위한 응용 분야 전망에 대해 설명합니다.

• 유전체학 연구: 유전자 은행 구상의 동향은 바이오뱅크 시장에서 이러한 시설에 대한 수요를 증가시키고 있습니다. 바이오뱅크는 유전체 연구를 위해 다양한 집단과 대량의 샘플을 제공합니다. 이 용도는 유전자 다형성, 질병 개발, 질병 관리의 치료와 같은 분야의 연구를 촉진합니다. 바이오뱅크 케어는 정밀하고 타겟팅된 의료의 다른 분야의 성장을 돕는 유전체학 연구의 일부가 될 것으로 보입니다.
• 개인맞춤의료: 개인맞춤의료는 바이오뱅크의 기회에 있어 고민거리이며, 이 분야의 성장은 놓칠 수 없는 기회입니다. 바이오뱅크는 현재 개인 맞춤형 치료와 신약개발을 지원하기 위해 실제 생물학적 표본과 상세한 임상 병력을 이용한 연구를 촉진하는 위치에 있습니다. 이를 응용하면 보다 신뢰할 수 있는 진단과 환자의 질병을 보다 정확하게 파악한 치료가 가능해져 개인 맞춤형 의료 분야의 발전을 더욱 촉진할 수 있습니다.
• 공중보건 연구: 바이오뱅크는 질병 발생, 질병 발생에 영향을 미치는 요인, 질병 통제 및 예방을 측정하는 연구를 포함하되 이에 국한되지 않는 역학 연구뿐만 아니라 건강 기반 연구에 필수적인 샘플 공급원입니다. 성장 기회에는 역학 및 공중보건 접근에 필수적인 바이오뱅크 자원의 강화가 포함됩니다. 이를 통해 공중보건 문제를 해결하고 효과적인 보건 전략과 프로그램을 개발 및 실행할 수 있는 역량을 강화할 수 있습니다.
• 의약품 개발 및 임상시험: 바이오뱅크는 모든 요구에 대응할 수 있는 생물학적 연구 자료를 제공하기 때문에 의약품 개발 및 임상 연구의 핵심입니다. 이러한 기회에 참여한다는 것은 의약품 개발 및 임상 연구 요구에 대해 제약 회사 및 연구 회사와 협력하는 것을 의미합니다. 이 용도는 의약품 개발 프로세스를 개선하면서 잠재적인 의약품의 창출을 가속화합니다.
• 질병 특이적 바이오뱅크: 질병 특이적 바이오뱅크의 개발은 암, 심혈관 질환, 희귀 유전성 질환 등의 구성적 바이오뱅크가 설립될 가능성이 있기 때문에 또 다른 성장 분야입니다. 이러한 바이오뱅크는 질병, 바이오마커, 치료법에 대한 이해를 높이는 데 도움이 될 수 있습니다. 이 용도는 특정 연구 작업을 촉진하지만 특정 질병의 진단 및 치료 요구를 더욱 발전시킬 수 있습니다.

전략적 바이오 뱅킹은 바이오 뱅킹 시장에 출현한 기회를 간과하고 있습니다. 유전체학 연구, 개인 맞춤형 의료, 공중보건 연구, 의약품 개발, 질병 특이적 바이오뱅크는 기회와 영향력이 확대되는 분야입니다. 이러한 기회를 활용하면 연구를 발전시키고, 개인 의료를 개선하고, 공중보건의 중대한 문제를 해결할 수 있습니다.

바이오뱅크 시장 활성화 요인 및 과제

바이오뱅크 시장은 기술, 규제, 경제 등 다양한 시장 성장 촉진요인과 과제에 의해 특징지어집니다. 이해관계자들은 시장 성장 촉진요인과 과제를 이해함으로써 시장에 진입하고, 증가하는 기회를 활용해야 합니다.

바이오뱅크 시장을 견인하는 요인은 다음과 같습니다.

• 개인맞춤형 의료에 대한 수요 증가: 최근 개인맞춤형 의료에 대한 관심이 높아지면서 바이오뱅크 시장이 크게 성장하고 있습니다. '맞춤 치료'라는 용어는 이러한 치료를 제공하기 위해 필요한 대량의 생물학적 및 임상 데이터를 필요로 하는 치료의 개념을 명확하게 구조화한 것입니다. 바이오뱅크는 개인 맞춤형 의료를 연구하고 의료 서비스를 개선하기 위해 광범위하고 종합적이며 정교한 샘플 컬렉션을 제공함으로써 이러한 요구 사항을 지원하고 있습니다.
• 연구 이니셔티브의 새로운 영역으로의 진입: 유전체학, 역학, 연구개발 등 연구 이니셔티브의 범위가 확대됨에 따라 바이오뱅크 자원에 대한 수요가 증가하고 있습니다. 이러한 연구 이니셔티브의 성장을 이해하면, 더 많은 생물학적 표본이 필요하며, 그 표본은 특이적이면서 동시에 쉽게 구할 수 있고 접근하기 쉬워야 합니다. 바이오뱅크는 의미 있는 과학적 기여를 위해 보유하고 있는 생물 시료의 수를 늘리고 다양한 연구 목적에 대응할 수 있는 범위를 넓히는 과정에 착수하고 있습니다.
• 정부 및 기관 자금 지원: 바이오뱅크 구축 및 관련 연구를 위해 정부 및 기관에서 제공하는 자금은 종종 시장의 핵심적인 성장 요인으로 작용합니다. 자금 지원은 새로운 바이오뱅크의 설립, 기존 바이오뱅크의 확장, 연구 결과의 개선 및 공유에 도움이 됩니다. 바이오 뱅킹 이니셔티브에 대한 투자 증가는 끊임없는 연구가 진행되는 이 시기에 고급 자원을 창출하는 데 도움이 됩니다.
• 국제 협력과 데이터 공유: 국제적인 협업과 데이터 공유가 바이오뱅크 시장의 성장을 가속하고 있으며, 이로 인해 더 크고 이질적인 데이터 세트를 다루기가 더 쉬워지고 있습니다. 국제적인 파트너십과 네트워크를 통해 연구와 지식 교환의 기능이 개방되고 있습니다. 이러한 추세로 인해, 과거에는 시간이 오래 걸리던 연구가 인력과 바이오뱅크의 자원을 활용함으로써 더 나은 더 빠른 과학을 육성할 수 있게 되었습니다.

바이오뱅크 시장의 과제는 다음과 같습니다.

• 규제와 윤리 문제: 규제와 윤리 준수는 바이오 뱅킹에 있어 시장원리 이상의 의미를 갖습니다. 데이터와 그 보호, 관련자의 동의, 시료 취급에 관한 정책을 다루는 것은 매우 시간이 많이 걸리고 비용이 많이 드는 사업입니다. 바이오뱅크의 구조 및 운영 프레임워크의 신뢰성과 무결성을 유지하기 위해서는 윤리적 고려와 규제 측면을 충족시켜야 하는 것으로 인식되고 있습니다.
• 데이터 안전, 보호, 프라이버시: 데이터 보안 및 프라이버시 관련 문제는 바이오 뱅킹 시장의 과제 중 하나입니다. 지극히 개인적인 건강 및 생물학적 데이터를 유출 및 무단 액세스로부터 보호하는 것은 문제입니다. 바이오매스 데이터를 위험으로부터 보호하고, 바이오뱅크와 그 업무에 대한 사회적 신뢰를 확보하기 위해 사이버 보안의 실천과 법적 조치를 취해야 합니다.
• 비용 및 인프라 자원 관리: 바이오뱅크의 설립과 운영에는 많은 재정적 투자가 필요하며, 특히 소규모 기관에게는 어려움이 따릅니다. 필요한 주요 활동 중 하나는 운영 비용을 관리하면서 장비, 정보 기술 시스템 및 인적 자원을 위한 자금을 조달하는 것입니다. 비용 절감과 적절한 자원 관리 관행은 바이오뱅크의 지속가능성을 달성하는 데 있어 매우 중요한 요소입니다.

이 세 가지 결론이 달성되어야 하는 구체적인 이유를 설명하기 위해 더 많은 연구가 진행되었고, 바이오뱅크의 이론적 기반은 많은 응용과학사회학과 마찬가지로 발전해 왔습니다. 또한, 기술 혁명, 의료 산업의 개인화 추세, 연구 활동의 성장을 포함한 주요 동향이 바이오뱅크 시장을 형성하고 있습니다. 이러한 촉진요인과 시장 문제를 해결하는 것은 성장 기회를 활용하고, 연구 잠재력을 높이고, 변화하는 바이오뱅크 현실을 극복하기 위해 필수적입니다.

목차

제1장 주요 요약

제2장 세계의 바이오뱅크 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019년-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 바이오뱅크 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 바이오뱅크 시장 : 시료 유형별
  • 혈액 제품
  • 인체조직
  • 세포주
  • 핵산
  • 체액
  • 인간 배설물
• 세계의 바이오뱅크 시장 : 제품 및 서비스별
  • 장비
  • 소모품
  • 서비스
  • 소프트웨어
• 세계의 바이오뱅크 시장 : 용도별
  • 재생의료
  • 생명과학 연구
  • 임상 연구
• 세계의 바이오뱅크 시장 : 최종 용도별
  • 제약 기업 및 바이오테크놀러지 기업, CRO(의약품 임상시험수탁기관)
  • 학술연구기관
  • 병원

제4장 지역별 시장 동향과 예측 분석(2019년-2031년)

• 세계의 바이오뱅크 시장 : 지역별
• 북미의 바이오뱅크 시장
• 유럽의 바이오뱅크 시장
• 아시아태평양의 바이오뱅크 시장
• 기타 지역의 바이오뱅크 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 바이오뱅크 시장 성장 기회 : 시료 유형별
  • 세계의 바이오뱅크 시장 성장 기회 : 제품 및 서비스별
  • 세계의 바이오뱅크 시장 성장 기회 : 용도별
  • 세계의 바이오뱅크 시장 성장 기회 : 최종 용도별
  • 세계의 바이오뱅크 시장 성장 기회 : 지역별
• 세계 바이오뱅크 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 바이오뱅크 시장 생산능력 확대
  • 세계 바이오뱅크 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Thermo Fisher Scientific
• PHC Holdings
• Becton
• Dickinson and Company
• QIAGEN N.V.
• Merck KGaA
• Avantor
• Cryoport
• Tecan Trading
• Azenta

영문목차

The future of the global biobanking market looks promising with opportunities in the pharmaceutical & biotechnology company and CRO, academic & research institute, and hospital markets. The global biobanking market is expected to reach an estimated $6.8 billion by 2031 with a CAGR of 10.5% from 2025 to 2031. The major drivers for this market are the growing demand for genetic testing and precision medicine, the rising popularity of preserving newborns' cord blood stem cells, and the emergence of virtual biobanking software.

• Lucintel forecasts that, within the product & service category, equipment is expected to witness the highest growth over the forecast period.
• Within the application category regenerative medicine will remain the largest segment in the forecast period.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Biobanking Market

The biobanking market is changing currently due to the occurrence of new technologies, the rise of new research, and changing policies. New trends signal the movement of biobanks in terms of operations, use of information, and the role played in biomedical research. Such trends are important to those interested in taking advantage of the new, fast-developing, biobanking environment.

• Advanced Technologies Adoption: In order to improve data analysis and sample processing, biobanks are integrating sophisticated tools such as high-throughput sequencing, NGS, and artificial intelligence among others. These technologies maximize the effectiveness of biobank tasks making it possible to conduct in-depth research to reveal genetic and environmental risk factors of health and diseases including illness and stress.
• Growth of Personalized Medicine: One of the trends of the market is also the old reason for the increasing loud demand for bank data that focuses on the cure of a certain disease. New populations and new clinical collections are also expanding and biobanks are making possible research into developing individualized therapies and precision medicine. This trend helps to develop more accurate treatment options and improve the efficacy of medical treatment.
• Safeguarding of Data and its Confidentiality: As focus increases with regard to data privacy and security, biobanks have implemented deep-rooted systems for the protection of such data. Adhering to regulatory frameworks like GDPR and HIPAA has become a vision, and biobanks have stepped up into new horizons of data security including the safeguarding of health and biological data and embracing confidentiality.
• Building of Centrally Managed and Region-Wise Located Biobanks: This current trend has been noticed in numerous countries where they are establishing a common biobank or biobanks with regional offices to enhance population-based studies and other health-related research on a large pop
• Combination of Biobanks and Sharing of Data: More emphasis is made on the increase of the combination, and sharing of data, of the biobanks and research institutions. There are emerging partnerships and networks that make it possible for scientists to utilize many datasets, from which a wide array of research can be pursued, speeding up the pace of discovery. This trend increases the worth of biobank resources and allows for more extensive and effective research.

Building of Centrally Managed and Region-Wise Located Biobanks: This current trend has been noticed in numerous countries where they are establishing a common biobank or biobanks with regional offices to enhance population-based studies and other health-related research on a large pop

Recent Developments in the Biobanking Market

Recent transitions in the biobanking market are characterized by improvements in technological infrastructural and research parameters. These developmental milestones are likely to revolutionize biobanking as they will offer new perspectives on biological sample collection, handling, and analysis for research. Knowledge of these developments is important for the players in the market to understand where the market is headed and identify new possibilities.

• Establishment of Large-Scale Biobanks: The establishment of large-scale biobanks like the All of Us Research Program in the U.S. and the European and Asian national biobanks is worth noting. These biobanks focus on harvesting a wide and rich array of biological samples to conduct extensive research population projects and customized treatment. They deepen the level of detail that can be addressed and assist cutting-edge research in genetics and population health.
• Combining the Various Areas of Genomics with High Throughput Technologies: The combining of genomics and biobanks with high-throughput practices is contributing to the development of research effort expansion. The standard operating procedures include high-throughput sequencing and genomic analysis which now allows the in-depth evaluation of genetic materials and how they affect health and disease. This advancement leads to the generation of more targeted and effective research, which in turn allows for deeper insights and the eradication of even more diseases.
• Biobank Information Management System's Improvements: The recent trends in biobank data management systems are enhancing the effectiveness and speed with which biobanks are operating. Improved techniques of handling the biorepository data as well as bioinformatics software help in proper structuring, dissecting, and disseminating the Biobank data. These systems facilitate the incorporation of different types of data sets and streamline the workflows, hence improving the research output.
• More Attention is Given to Bioethics and Regulations: More attention is paid to the ethical and regulatory perspectives of biobanking. There are measures being put in place by biobanks to make sure that ethics and governance principles such as consent, confidentiality, and sample handling are being followed. This concern improves the efficiency and reliability of the operations of biobanks and promotes compliance with accepted standards.
• Increasing the Scale of Biobank Networks and Advances in Collaborations: The growing network and collaboration of the biobanks is an interesting trend as the biobanks are ready to collaborate for sharing resources and data. These collaborations allow making use of the greater and more varied datasets, benefiting from the synergies of research, and speeding the process of science. Embedding biobanks into global networks helps achieve more complete and significant research results.

Important recent advances in the biobanking field such as the creation of population biobanks, adoption of new information technologies, progress in information management, fulfillment of regulative requirements, and enlargements of networks are defining the evolution of the markets. These changes broaden the possibilities of conducting biobanking research, facilitate personalized medicine, and bring about progress in the healthcare industry as well as in biomedical research.

Strategic Growth Opportunities for Biobanking Market

In the biobanking market, there are several opportunities for growth in terms of the different applications available. By applying these opportunities, stakeholders will be able to enlarge their engagement in and ultimately influence, research and public health. This overview focuses on the biobanking framework growth dynamics and explains the key growth patterns along with prospects for wider applications defined by the domain extension of the market.

• Genomics Research: The trends of Geno-bank initiatives are increasing the demand for such a facility in the biobanking market. The biobanks provide a variety of populations and a large sample for genomic research. This application promotes research in the fields of genetic polymorphism, disease development, and treatments in disease management. Transferring the care of biobanks is looking to portions of the genomics research that will help grow those in other areas of precise and targeted medicine.
• Personalized Medicine: Personalized medicine is a bane for biobank opportunities and the growth of this segment cannot be overlooked. Biobanks are now positioned to facilitate research with actual biological specimens and detailed clinical history in support of individualized therapies and drug discovery. This application allows a more reliable diagnosis and a treatment that better targets the disease of the patient and further promotes the development of the personalized medicine field.
• Public Health Research: Biobanks are sources of samples essential for health-based research as well as for epidemiological studies including but not limited to the studies measuring disease occurrence, factors influencing the occurrence of diseases, and their control or prevention. Growth opportunities include enhancing crucial biobank resources for epidemiological and public health approaches. This enhances the ability to solve public health problems as well as design and implement effective health strategies and programs.
• Drug Development and Clinical Trials: Biobanks are the heart of any drug development or any clinical studies, as they offer biological investigation material for all possible needs. Joining such opportunities means cooperation with pharmaceutical and research companies for the needs of drug development and clinical studies. This application hastens the generation of potential drugs while improving the processes of drug development.
• Disease-Specific Biobanks: Developing disease-specific biobanks is another area for growth as constitutive biobanks such as the ones for cancer, cardiovascular diseases, or rare genetic diseases may be set up. These biobanks are beneficial for the investigation of a better understanding of the disease, its biomarkers, and its treatment options. This application promotes specific research work, however, further advances the needs of diagnosis and treatment of specific diseases.

Strategic biobanking miscues opportunities emerging in the biobanking market. Genomics research, personalization medicine, public health research, drug development, and disease-specific biobanks indicate areas of growing opportunity and impact. Taking advantage of these opportunities engages progress in research, improves individual healthcare, and solves significant public health problems.

Biobanking Market Driver and Challenges

The biobanking market is characterized by various drivers and challenges, including, but not limited to, technology, regulation, and economy. Stakeholders need to appreciate such drivers and challenges in order to maneuver into the market and harness such opportunities that are ever on the rise.

The factors responsible for driving the biobanking market include:

• Increasing Demand Text for Personalized Medicine: Resent emphasis on personalized medicine is a major booster in the biobanking market. The term "personalized treatment" clearly structures the concept of therapy requiring a great amount of biological and clinical data needed to provide such treatment. Biobanks assist this requirement with their provision of broad, comprehensive, and elaborate sample collections to investigate personalized medicine and enhance healthcare services.
• Inclusion of New Areas in Research Initiatives: The demand for biobank resources is increasing because the scope of research initiatives including genomics, epidemiology, and drug development is broadening. Understanding the growth of these research efforts, there is therefore an increasing demand for more biological specimens that are specific as well as easily available and accessible. Biobanks have embarked on the process of increasing the number of biological specimens that they have and the scope at which they serve different research purposes to make meaningful scientific contributions.
• Government and Institutional Funding: Often, funding provided by the government and the institutions for building and biobanking and research related to it constitutes the core growing factor of the market. Funding helps to set up new biobanks and extend existing ones, to improve research work and to help share it. Increased investment in biobanking initiatives helps to create advanced resources during this period of constant research.
• International Collaboration and Data Sharing: International collaboration and data sharing are stimulating the growth of the biobanking market and due to this reason, it is easier to work with larger and more heterogeneous sets of data. Research and knowledge exchange capabilities are opened up through international partnerships and networks. This trend fosters better and faster science as research that would have taken longer to conduct is made possible by the availability of talent and biobank resources.

Challenges in the biobanking market are:

• Regulation and Ethical Issues: Regulatory and ethical compliance is more than one of the market forces for biobanking. Dealing with policies regarding the data and its protection, consent of parties and sample handling can be a very slow undertaking quite expensive. It is recognized that ethical considerations and regulatory aspects should be met to retain the credibility and integrity of the biobank structure and operational framework.
• Data Security, Protection, and Privacy: Data security and privacy-related issues are among the biobanking market challenges. Safeguarding very personal health-biological data from leakage and abusive access is an issue. Cybersecurity practices and legal measures should be performed to protect biomass data from harm and ensure public confidence in biobanks and their practices
• Costs and Infrastructure Resource management: Setting up and running biobanks will involve significant financial investments which particularly for small institutions can prove a challenge. One of the major activities that will be required is sourcing funds for equipment, information technology systems as well as human resources while controlling operational costs. Cost containment and proper resource management practices will be critical factors in the achievement of sustainability of the biobank.

Further studies have been done to illustrate specific reasons why these three conclusions should be achieved, the theoretical base of biobanking has been developed as much of the applied sociology of science. Further, the major forces including but not limited to the technological revolution, the personalization trend in the healthcare industry, and the growth in research activity take the shape of the biobanking market. Tackling these drivers and Market problems is essential for utilizing growth opportunities, increasing the research possibilities, and conquering the changing reality of biobanking.

List of Biobanking Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biobanking companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biobanking companies profiled in this report include-

• Thermo Fisher Scientific
• PHC Holdings
• Becton
• Dickinson and Company
• QIAGEN N.V.
• Merck KGaA
• Avantor
• Cryoport
• Tecan Trading
• Azenta

Biobanking by Segment

The study includes a forecast for the global biobanking market by sample type, product & service, application, end use, and region.

Biobanking Market by Sample Type [Analysis by Value from 2019 to 2031]:

• Blood Products
• Human Tissues
• Cell Lines
• Nucleic Acids
• Biological Fluids
• Human Waste Products

Biobanking Market by Product & Service [Analysis by Value from 2019 to 2031]:

• Equipment
• Consumables
• Services
• Software

Biobanking Market by Application [Analysis by Value from 2019 to 2031]:

• Regenerative Medicine
• Life Science Research
• Clinical Research

Biobanking Market by End Use [Analysis by Value from 2019 to 2031]:

• Pharmaceutical & Biotechnology Companies and CROs
• Academic & Research Institutes
• Hospitals

Biobanking Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Biobanking Market

The biobanking market has evolved positively due to technological advancements, increased research demands, and a focus on personalized medicine. Biobanks play a crucial role in medical research and therapy development by collecting and preserving biological specimens. Insights into the biobanking landscape in the USA, China, Germany, India, and Japan illustrate the scale and direction of the market amid changing policies and technologies.

• United States: In the U.S., biobanking has made significant strides through the integration of high-throughput gene sequencing and bioinformatics. Initiatives like the All of Us Research Program focus on broad data collection to improve services. Increased funding and public-private partnerships are enhancing biobank capabilities and supporting advances in disease therapeutics and research.
• China: China has heavily invested in its biobanking network, driven by government policies aimed at enhancing biotechnological capabilities and healthcare systems. This includes creating large-scale biobanks and forming collaborations with global organizations. China is also working to advance its legislative policies to ensure the ethical use and security of biological materials and data.
• Germany: Germany's biobank growth is supported by robust legislation and high standards for handling patient data and bioethics. The German Biobank Node promotes European data collection and sharing for scientific purposes. Recent efforts focus on integrating biobank data with clinical information to enhance research and precision medicine initiatives.
• India: India's biobanking segment is developing due to increasing research activities and government support for biomedical initiatives. New biobanks and expansions of existing ones, such as the Indian Genome Variation Consortium, are emerging. The country aims to strengthen infrastructure and data support for genomics, personalized medicine, and public health research through international partnerships.
• Japan: Japan's biobanking market is evolving through technological advancements and personalized medicine strategies. Recent developments include large-scale biobanks and partnerships with international counterparts. Japan is also working to integrate biobank data with electronic health records to improve research and clinical care while enhancing regulatory and ethical frameworks.

Features of the Global Biobanking Market

Market Size Estimates: Biobanking market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Biobanking market size by various segments, such as by product & service, sample type , application, end use industry, and region in terms of ($B).

Regional Analysis: Biobanking market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product & service, sample types , applications, end use industries, and regions for the biobanking market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biobanking market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the biobanking market by sample type (blood products, human tissues, cell lines, nucleic acids, biological fluids, and human waste products), product & service (equipment, consumables, services, and software), application (regenerative medicine, life science research, and clinical research), end use (pharmaceutical & biotechnology companies and CROs, academic & research institutes, and hospitals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Biobanking Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Biobanking Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Biobanking Market by Sample Type
  • 3.3.1: Blood Products
  • 3.3.2: Human Tissues
  • 3.3.3: Cell Lines
  • 3.3.4: Nucleic Acids
  • 3.3.5: Biological Fluids
  • 3.3.6: Human Waste Products
• 3.4: Global Biobanking Market by Product & Service
  • 3.4.1: Equipment
  • 3.4.2: Consumables
  • 3.4.3: Services
  • 3.4.4: Software
• 3.5: Global Biobanking Market by Application
  • 3.5.1: Regenerative Medicine
  • 3.5.2: Life Science Research
  • 3.5.3: Clinical Research
• 3.6: Global Biobanking Market by End Use
  • 3.6.1: Pharmaceutical & Biotechnology Companies and CROs
  • 3.6.2: Academic & Research Institutes
  • 3.6.3: Hospitals

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Biobanking Market by Region
• 4.2: North American Biobanking Market
  • 4.2.1: North American Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.2.2: North American Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.3: European Biobanking Market
  • 4.3.1: European Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.3.2: European Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.4: APAC Biobanking Market
  • 4.4.1: APAC Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.4.2: APAC Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.5: ROW Biobanking Market
  • 4.5.1: ROW Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.5.2: ROW Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Biobanking Market by Sample Type
  • 6.1.2: Growth Opportunities for the Global Biobanking Market by Product & Service
  • 6.1.3: Growth Opportunities for the Global Biobanking Market by Application
  • 6.1.4: Growth Opportunities for the Global Biobanking Market by End Use
  • 6.1.5: Growth Opportunities for the Global Biobanking Market by Region
• 6.2: Emerging Trends in the Global Biobanking Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Biobanking Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biobanking Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Thermo Fisher Scientific
• 7.2: PHC Holdings
• 7.3: Becton
• 7.4: Dickinson and Company
• 7.5: QIAGEN N.V.
• 7.6: Merck KGaA
• 7.7: Avantor
• 7.8: Cryoport
• 7.9: Tecan Trading
• 7.10: Azenta